Chemotherapy-induced Anemia
Conditions
Brief summary
The aim of this study is to describe, in a real-life context, the impact of an epoetin alpha biosimilar, Retacrit®, on anaemia in patients receiving chemotherapy, according to concomitant iron supplementation.
Detailed description
This is a longitudinal, observational, prospective, multicentre, cohort study, conducted on a representative sample of public and/or private hospital-based oncologists and haematologists practicing in Metropolitan France.
Interventions
None listed
Sponsors
Hospira, now a wholly owned subsidiary of Pfizer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients, aged 18 years and older, seen by the oncologist or hematologist for chemotherapy. * Patients for whom the oncologist or hematologist has decided the initiation of an epoetin alpha biosimilar treatment (Retacrit®) for anemia. * Patients informed about the computer processing of their medical data and their right of access and correction.
Exclusion criteria
* Patients with hemoglobin concentrations \>11 g/dL. * Patients who have been transfused within the previous month. * Patients who are hypersensitive to erythropoietin or one of its excipients. * Patients participating or having participated in the previous month in a clinical trial in the field of anaemia in oncology. * Patients refusing to participate in the observational study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Impact of an epoetin alpha biosimilar with or without iron supplementation on chemotherapy-induced anemia | Patients are included at the time of the epoetin alpha biosimilar treatment initiation for chemotherapy-induced anemia and followed up to 12 to 16 weeks | The efficiency of epoetin alpha biosimilar will be assessed by the responders'rate according to European Society for Medical Oncology (ESMO) guidelines. This rate will be compared depending on the iron supplementation. The safety will be assessed by the record of adverse effects (serious or not) and treatment discontinuation. |
Secondary
| Measure | Time frame |
|---|---|
| Characteristics of patients receiving treatment with an epoetin alpha biosimilar, Retacrit®, for chemotherapy induced anaemia | Baseline visit |
| Procedures for evaluating possible iron deficiency and iron supplementation | At 12 to 16 weeks from baseline or at the end of chemotherapy |
| Impact of iron supplementation on the doses of Retacrit® used, and on treatment duration | At 12 to 16 weeks from baseline or at the end of chemotherapy |
| Experience of patients treated with Retacrit® | At 12 to 16 weeks from baseline or at the end of chemotherapy |
Countries
France
Outcome results
None listed